Combination Therapy of Senaparib and Bevacizumab for First-line Maintenance Therapy in Newly Diagnosed Advanced Homologous Recombination Proficient Ovarian Cancer Based on Exosome Protein Marker

NCT07120451 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

37

Enrollment

OTHER

Sponsor class

Conditions

Advanced Ovarian Cancer

Interventions

DRUG: Senaparib
DRUG: Bevacizumab

Sponsor

Fudan University